FDA 483 OBSERVATION · #118 OF 1,945 MOST-CITED
Environmental control Lack of or inadequate procedures
FDA cited this observation 258 times across 230 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
21 CFR 820.70 (Production and process controls) is a Quality System Regulation section; since QMSR took effect on 2 February 2026 FDA inspects this as “Control of Production and Service Provision”: 21 CFR 820.35 and 820.45, and ISO 13485 clause 7.5.1 (CP 7382.850 Attachment A).
The device Quality System Regulation requires that where environmental conditions could reasonably be expected to have an adverse effect on product quality, those conditions be controlled and the controls periodically inspected; this citation means the environmental-control procedures are missing or inadequate.
Why FDA writes it — FDA cites this when a manufacturer has not established or verified controls over conditions such as temperature, humidity, particulate, or bioburden that can degrade a device, because uncontrolled environment silently compromises product the firm cannot see failing until the field does.
- Identify which environmental conditions could adversely affect device quality and establish written procedures to control them.
- Define acceptance limits and periodically inspect and verify the controls and the systems that maintain them.
- Record environmental monitoring results and trigger corrective action when limits are exceeded.
- Assuming ambient conditions are adequate without a documented assessment of their effect on the specific device.
- Controls exist but are never periodically inspected or verified, so drift goes undetected.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.9× the rate of the average FDA-cited firm (15.2% vs 7.8%), across 230 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures to control environmental conditions have not been adequately established.
Procedures to control environmental conditions have not been adequately established.
Procedures to control environmental conditions have not been adequately established.
Procedures to control environmental conditions have not been adequately established.
Procedures to control environmental conditions have not been adequately established.
Procedures to control environmental conditions have not been adequately established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →